… in the 1980s, the improved safety of anti-haemophilia treatments, the arrival of recombinant
… patients with haemophilia are going through a real revolution and even haemophilia cure by …

… to review the pharmacokinetics of FVIII, FIX and FVIIa and to give an outline of clinical
applications to optimise the treatment of patients with haemophilia. The pharmacokinetics of factor …

… and patients, and other pharmacokinetic (PK) parameters … , individualised prophylaxis in
haemophilia to improve patient … (eg 4, 24 and 48 h for haemophilia A), by using the patient’s …

… safety, pharmacokinetics, and pharmacodynamics of rFVIIa in Japanese patients following
a single intravenous infusion at a dose of 120 µg/kg (study 1) and the safety … of haemophilic …

… The primary objective was to evaluate safety. Assessments of pharmacokinetics,
pharmacodynamics and subcutaneous concizumab immunogenicity were secondary objectives. …

… , we tested the safety, pharmacokinetics and pharmacodynamics of FVIIa … haemophilia A
patients with inhibitory antibodies against FVIII. The efficacy, pharmacokinetics (PK) and safety …

… Here, we report on the efficacy, safety and pharmacokinetics (PK) of a low-volume, highly
active, pdVWF/FVIII concentrate VONCENTO® in subjects with haemophilia A. This …

… methods for evaluating and monitoring haemophilia treatment.10, … pharmacokinetics (PK)
of rFVIIa after multiple doses (3×90 μg kg −1 ) vs a single dose (270 μg kg −1 ) in haemophilia …

… A (<1% of normal FVIII activity in blood) or haemophilia A … pharmacokinetics after single
and multiple (every 4 weeks) subcutaneous administration of 6 mg/kg emicizumab and safety. In …

… The lack of significant safety findings, specifically lack of any detected FIX inhibitors and all
… that the safety profile of IB1001 is acceptable for treatment of subjects with haemophilia B. …